Cargando…

Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations

Cefiderocol is a novel siderophore cephalosporin antibacterial with activity against carbapenem-resistant Gram-negative bacteria including Pseudomonas aeruginosa. We report a medically complex patient treated with compassionate use cefiderocol for an empyema caused by extensively drug-resistant P. a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kufel, Wesley D., Steele, Jeffrey M., Riddell, Scott W., Jones, Zachary, Shakeraneh, Pegah, Endy, Timothy P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300106/ https://www.ncbi.nlm.nih.gov/pubmed/32577400 http://dx.doi.org/10.1016/j.idcr.2020.e00863

Ejemplares similares

Cefiderocol is an effective topical monotherapy for experimental extensively-drug resistant Pseudomonas aeruginosa keratitis
por: Romanowski, Eric G., et al.
Publicado: (2023)

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019
por: Karlowsky, James A., et al.
Publicado: (2022)

Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa
por: Sadek, Mustafa, et al.
Publicado: (2022)

P44 Nosocomial neurosurgical meningitis due to XDR Pseudomonas aeruginosa: clinical experience with cefiderocol
por: Stevenson, D. R., et al.
Publicado: (2022)

769. Comparison of Vancomycin Continuous and Intermittent Infusion Dosing Strategies Among Patients in an Outpatient Antimicrobial Therapy Program
por: Shakeraneh, Pegah, et al.
Publicado: (2019)

Successful prolonged cefiderocol treatment of a chronic left pleural empyema caused by Pseudomonas aeruginosa in a patient affected by COVID-19: a case report
por: Borghesi, Luca, et al.
Publicado: (2021)

66. Impact of a Pharmacist-Driven Azithromycin De-escalation Protocol for Community-Acquired Pneumonia
por: Shakeraneh, Pegah, et al.
Publicado: (2020)

Combination of phage therapy and cefiderocol to successfully treat Pseudomonas aeruginosa cranial osteomyelitis
por: Simner, Patricia J., et al.
Publicado: (2022)

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa
por: Edgeworth, Jonathan D, et al.
Publicado: (2019)

1246. Clinical isolates of Pseudomonas aeruginosa Harbor Preexisting Changes in TonB-dependent Receptors Associated with Decreased Susceptibility to Cefiderocol
por: Egge, Stephanie L, et al.
Publicado: (2021)

Successful use of prolonged cefiderocol monotherapy for the treatment of a complex pleural abscess caused by extensively drug-resistant (XDR) Pseudomonas aeruginosa
por: Brookfield, Charlotte, et al.
Publicado: (2023)

Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa
por: Chavda, A, et al.
Publicado: (2021)

Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2021)

Ceftazidime-avibactam and intrapleural amikacin therapy for extensively drug-resistant Pseudomonas aeruginosa thoracic empyema: A case report
por: Chen, Tzu-Ting, et al.
Publicado: (2022)

Empyema necessitans in an infant due to pseudomonas aeruginosa at a referral hospital in mogadishu, somalia: A case report
por: Mohamed, Yahye Garad, et al.
Publicado: (2021)

648. Cefiderocol as Rescue Therapy for Pseudomonas aeruginosa and Other Difficult-To-Treat Gram-Negative Infections
por: Chou, Andrew, et al.
Publicado: (2022)

Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program
por: Satlin, Michael J., et al.
Publicado: (2023)

2750. Pseudomonas aeruginosa infections treated with cefiderocol: associations of site of infection and time to first dose with outcomes in PROVE (Retrospective Cefiderocol Chart Review) Study
por: Marcella, Stephen, et al.
Publicado: (2023)

An Extensive Empyema
por: Chopra, B. L.
Publicado: (1936)

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa
por: Ito, Akinobu, et al.
Publicado: (2016)

Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City
por: Iregui, Alejandro, et al.
Publicado: (2020)

Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections
por: Meschiari, Marianna, et al.
Publicado: (2021)

Pyometra due to Pseudomonas aeruginosa
por: McLeod, Nathan, et al.
Publicado: (2019)

Investigating and Treating a Corneal Ulcer Due to Extensively Drug-Resistant Pseudomonas aeruginosa
por: Morelli, Morgan K., et al.
Publicado: (2023)

Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae
por: Ito, Akinobu, et al.
Publicado: (2019)

Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae
por: Ito, Akinobu, et al.
Publicado: (2018)

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia
por: Delgado-Valverde, Mercedes, et al.
Publicado: (2020)

P24 Cefiderocol activity against a multidrug-resistant (MDR) strain of Pseudomonas aeruginosa: a case report
por: Lim,, Felicia H., et al.
Publicado: (2022)

In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors
por: Shields, Ryan K, et al.
Publicado: (2023)

The effect of Cyclic-di-GMP on biofilm formation by Pseudomonas aeruginosa in a novel empyema model
por: Zhang, Li, et al.
Publicado: (2020)

DNase inhibits early biofilm formation in Pseudomonas aeruginosa- or Staphylococcus aureus-induced empyema models
por: Deng, Wusheng, et al.
Publicado: (2022)

The Effects of Sub-inhibitory Antibiotic Concentrations on Pseudomonas aeruginosa: Reduced Susceptibility Due to Mutations
por: Ramsay, Kay A., et al.
Publicado: (2021)

1280. In-Vitro Activity of Cefiderocol, Imipenem/Relebactam, & Ceftazidime/Avibactam in Ceftolozane/Tazobactam Resistant Strains of Multidrug Resistant Pseudomonas aeruginosa
por: Navas, Daniel, et al.
Publicado: (2020)

1256. Clinical Response by Minimum Inhibitory Concentrations in Carbapenem-Resistant Pseudomonas aeruginosa Infections under Cefiderocol Compassionate Use Program
por: Satlin, Michael J, et al.
Publicado: (2021)

Clinical Cure of a Difficult-to-Treat Resistant Pseudomonas aeruginosa Ventriculitis Using Cefiderocol: A Case Report and Literature Review
por: Marcelo, Cristina, et al.
Publicado: (2022)

Dissemination of transposon Tn6001 in carbapenem-non-susceptible and extensively drug-resistant Pseudomonas aeruginosa in Taiwan
por: Tseng, Sung-Pin, et al.
Publicado: (2009)

Hyperammonemia Due to Empyema
por: Wada, Hiroshi, et al.
Publicado: (2023)

Susceptibility Rates of Pseudomonas Aeruginosa Strains to Quinolones
por: Adhikari, Luna, et al.
Publicado: (2010)

Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital
por: Weber, C., et al.
Publicado: (2022)

Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii
por: Raro, Otávio Hallal Ferreira, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s3883gh30hl1sfelkth15lq5pi